Randomized Controlled Trial of Remote Symptoms Monitoring With Resilience PRO Compared to Care As Usual Only
Recruiting
Phase 3
Interventional Study
Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Supportive Care
- Participants needed
- 1,458 (estimated)
- Sponsor
- Resilience · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this clinical trial is to learn if Resilience PRO, a digital solution performing remote symptoms monitoring, can improve the quality of life of patients with a diagnosis of cancer receiving systemic anticancer treatment.
The main question it aims to answer is:
\- Do patients with a diagnosis of cancer receiving systemic anticancer therapy and using Resilience PRO have an improved qua…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age: Adults ≥ 18 years.
* Informed Consent: Patient giving signed informed consent to participate in the RC - 102 clinical study.
* Diagnosis: Patients with cancer at any stage.
* Systemic Treatment
* Remote Monitoring Eligibility: Access to a smartphone
* Language: Ability to…
Contacts